Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 5/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL737953 | 0.88 | NPC1 (0.35) | MAPTUSP2ARCA1CA2 | |
| SCHEMBL472625 | 0.88 | LMNA (0.42) | MAPTUSP2ARCA1HPGD | |
| SCHEMBL472288 | 0.88 | MAPT (0.37) | MAPTUSP2 | |
| SCHEMBL739419 | 0.86 | USP2 (0.32) | MAPTUSP2CA1CA2 | |
| SCHEMBL472629 | 0.86 | MAPT (0.34) | MAPTUSP2CA1CA2HPGD | |
| SCHEMBL737376 | 0.85 | SMN1; SMN2 (0.33) | MAPTPKMUSP2TTRCA1 | |
| Ammonia Solution, Strong SCHEMBL27964641 | 0.85 | MAPT (0.33) | MAPTUSP2CA1CA2HPGD | |
| SCHEMBL1798362 | 0.84 | CASP1 (0.33) | MAPTUSP2CA1CA2 | |
| SCHEMBL472676 | 0.84 | NCOA1 (0.33) | MAPTUSP2CA1CA2HPGD | |
| SCHEMBL3116206 | 0.84 | VCAM1 (0.44) | MAPTUSP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987464-B2 | Isoxazoline-substituted benzamide compound and pesticide | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20140135496-A1 | ISOXAZOLINE-SUBSTITUTED BENZAMIDE COMPOUND AND PESTICIDE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-05-15 | — | — | US | disclosed |
| US-8673951-B2 | Isoxazoline-substituted benzamide compound and pesticide | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-1932836-B1 | ISOXAZOLINE-SUBSTITUTED BENZAMIDE COMPOUND AND HARMFUL ORGANISM-CONTROLLING AGENT | NISSAN CHEMICAL IND LTD (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-20110144334-A1 | ISOXAZOLINE-SUBSTITUTED BENZAMIDE COMPOUND AND PESTICIDE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-7951828-B1 | Isoxazoline-substituted benzamide compound and pesticide | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| EP-1932836-A1 | ISOXAZOLINE-SUBSTITUTED BENZAMIDE COMPOUND AND HARMFUL ORGANISM-CONTROLLING AGENT | Nissan Chemical Industries, Ltd. (JP) | 2008-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144334-A1 | ISOXAZOLINE-SUBSTITUTED BENZAMIDE COMPOUND AND PESTICIDE | OR10J3, OR51E2, ORMDL3 | ALOX12 2045/4885GPR35 211/4885MAPT 4464/4885 |
| US-20140135496-A1 | ISOXAZOLINE-SUBSTITUTED BENZAMIDE COMPOUND AND PESTICIDE | OR10J3, OR51E2, ODC1 | ALOX12 3272/4885GPR35 392/4885MAPT 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.